Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Director departure
Moderna, Inc. (MRNA) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/03/2023 8-K Quarterly results
Docs: "Moderna Reports Second Quarter 2023 Financial Results and Provides Business Updates Second quarter 2023 revenues of $0.3 billion&#59; net loss of $1.4 billion and loss per share of $3.62"
02/23/2023 8-K Quarterly results
Docs: "Moderna Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Provides Business Updates Fourth quarter 2022 revenues of $5.1 billion&#59; GAAP net income of $1.5 billion and GAAP diluted EPS of $3.61"
11/03/2022 8-K Quarterly results
08/03/2022 8-K Quarterly results
Docs: "Moderna Reports Second Quarter 2022 Financial Results and Provides Business Updates Second quarter 2022 revenues of $4.7 billion&#59; GAAP net income of $2.2 billion and GAAP diluted EPS of $5.24"
05/04/2022 8-K Quarterly results
Docs: "Moderna Reports First Quarter 2022 Financial Results and Provides Business Updates First quarter 2022 revenues of $6.1 billion&#59; GAAP net-income of $3.7 billion and GAAP diluted EPS of $8.58"
02/24/2022 8-K Quarterly results
11/04/2021 8-K Quarterly results
Docs: "Moderna Reports Third Quarter Fiscal Year 2021 Financial Results and Provides Business Updates"
10/29/2020 8-K Quarterly results
Docs: "Moderna Reports Third Quarter 2020 Financial Results and Provides Business Updates"
08/05/2020 8-K Quarterly results
05/07/2020 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15 of The Securities Exchange Act of 1934 Date of Report : May 5, 2020 MODERNA, INC. Delaware 001-38753 81-3467528 200 Technology Square Cambridge, MA 02139 : 714-6500 N/A Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement communications pursuant to Rule 13e-4 under the Exchange Act ) Secu...",
"Executive Retention and Separation Agreement, by and between Moderna, Inc. and Lorence Kim, M.D",
"Moderna Reports First Quarter 2020 Financial Results and Provides Business Updates"
02/26/2020 8-K Quarterly results
11/06/2019 8-K Quarterly results
Docs: "Moderna Provides Business Updates and Reports Third Quarter 2019 Financial Results"
08/07/2019 8-K Quarterly results
Docs: "MODERNA PROVIDES BUSINESS UPDATES AND REPORTS SECOND QUARTER 2019 FINANCIAL RESULTS"
05/09/2019 8-K/A Quarterly results
Docs: "MODERNA REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATES Rare Diseases: New development candidate announced for glycogen storage disease type 1a , a rare metabolic disorder; Company now has five rare disease programs in its pipeline Immuno-Oncology: Two personalized cancer vaccine abstracts to be presented at the 2019 ASCO Annual Meeting Infectious Diseases: Merck submitted an IND for mRNA-1172, a more potent RSV vaccine development candidate; development paused for first RSV candidate, mRNA-1777 Ended quarter with $1.55 billion in cash, cash equivalents and investments CAMBRIDGE, Mass., May 8, 2019 -- Moderna, Inc. , a clinical stage biotechnology company pioneering messenger RNA therapeutics and vaccines to create a new generation of transformative medicines for..."
05/08/2019 8-K Quarterly results
Docs: "MODERNA REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATES Rare Diseases: New development candidate announced for glycogen storage disease type 1a , a rare metabolic disorder; Company now has five rare disease programs in its pipeline Immuno-Oncology: Two personalized cancer vaccine abstracts to be presented at the 2019 ASCO Annual Meeting Infectious Diseases: Merck submitted an IND for mRNA-1172, a more potent RSV vaccine development candidate; development paused for first RSV candidate, mRNA-1777 Ended quarter with $1.55 billion in cash, cash equivalents and investments CAMBRIDGE, Mass., May 8, 2019 -- Moderna, Inc. , a clinical stage biotechnology company pioneering messenger RNA therapeutics and vaccines to create a new generation of transformative medicines for..."
03/06/2019 8-K Quarterly results
Docs: "MODERNA REPORTS 2018 FOURTH QUARTER AND FULL YEAR FINANCIAL RESULTS AND HIGHLIGHTS RECENT PIPELINE PROGRESS",
"Moderna, Inc. 2018 Shareholder Letter"

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy